Yellowbird Diagnostics, specializing in biomedical imaging solutions across commonly used clinical imaging technologies, recently announced closing an oversubscribed funding round. With this funding, Yellowbird aims to launch first-in-human scans and a Phase 1 clinical trial for their lead product, NeuCaVis, unlocking the full potential of PET imaging.
Yellowbird Diagnostics is an OBIO® member, alumnus of the CAAP® program, and presented at the OBIO® Investment Summit.